Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 11/2006

01-11-2006 | Original Research Article

Bias due to False-Positive Diagnoses in an Automated Health Insurance Claims Database

Authors: Dr Stephan F. Lanes, Cynthia de Luise

Published in: Drug Safety | Issue 11/2006

Login to get access

Abstract

Background and objective: Automated database studies have become a cornerstone of drug safety assessment. To assess the reliability of automated data, we compared the hospitalisation and mortality rates among three similar studies of automated healthcare databases in North America.
Methods: Similar protocols were used to identify patients diagnosed with chronic obstructive pulmonary disease (COPD) who were treated with inhaled bronchodilators or inhaled corticosteroids in the Saskatchewan Health Database (SHD), the Kaiser Permanente Medical Care Program (KPMCP) of Northern California, and a proprietary automated insurance claims database available from i3® (formerly Ingenix®). Automated data were used to compute incidence rates of total hospitalisation, cardiovascular (CV) hospitalisation and hospitalisation due to several specific types of CV outcomes. Record linkage with registries of vital statistics was used to identify deaths, obtain death certificates, and compute rates of total mortality, CV mortality and deaths due to certain CV outcomes. We compared rates in the i3® population with rates in the other two populations using age-adjusted rate ratio estimates and 95% CIs.
Results: The i3® cohort had approximately one-half the rates of total mortality, CV mortality and total hospitalisations, but twice the rate of CV hospitalisations, compared with each of the other two database cohorts.
Discussion: The unexpectedly higher rates of CV hospitalisations in the i3® population are inconsistent with its lower CV mortality, total mortality and total hospitalisation rates. This discrepancy is not readily explained by a higher prevalence of CV disease or procedures, random variation or confounding. Instead, high CV hospitalisation rates in the i3® population are consistent with a high rate of false-positive diagnoses recorded on insurance billing claims.
Conclusion: These results underscore the importance of ensuring valid endpoints in automated claims databases.
Literature
1.
Harris G. Drug safety system is broken, a top FDA official says. New York Times 2005 Jun 9; Late Edition-Final, Sect. A: 24 (col 4)
2.
Fuhrmans V. Early-warning tool for unsafe drugs. Wall Street Journal 2005 Apr 28, D4
3.
Downey W, Stang MR, Beck P, et al. Health services databases in Saskatchewan. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. New York (NY): John Wiley & Sons Ltd, 2005: 295–310
4.
Selby JV, Smith DH, Johnson ES, et al. Kaiser permanente medical care program. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. New York (NY): John Wiley & Sons Ltd, 2005: 241–60
5.
Shatin D, Rawson NSB, Stergachis A. UnitedHealth Group. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. New York (NY): John Wiley & Sons Ltd, 2005: 271–80
6.
Lanza L, Norman H, Quinn SG, et al. A cohort study of cardiovascular conditions in COPD. Auburndale (MA): Ingenix Epidemiology, a UnitedHealth Group Company, 2003 Jul 29 (data on file)
7.
de Luise C, Lanes S, Curkendall S, et al. Cardiovascular morbidity and mortality among persons with chronic obstructive pulmonary disease [abstract]. Pharmacoepidemiol Drug Saf 2004; 13: S238
8.
Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–75CrossRefPubMed
9.
Curkendall S, de Luise C, Jones J, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease. Saskatchewan, Canada. Ann Epidemiol 2006; 16: 63–70CrossRefPubMed
10.
National Hospital Discharge Survey [online]. Available from URL: http://​www.​cdc.​gov/​nchs/​data/​ad/​ad319.​pdf [Accessed 2005 Jul 7]
11.
Quam L, Ellis LBM, Venus P, et al. Using claims data for epidemiologic research: the concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993; 131: 498–507CrossRef
12.
Lanza L, Dreyer NA, Schultz NJ, et al. Use of insurance claims in epidemiologic research: identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis and renal disease. Pharmacoepidemiol Drug Saf 1995; 4: 239–48CrossRef
13.
Sands BE, Duh MS, Cali C, et al. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. Pharmacoepidemiol Drug Saf 2006; 15: 47–56CrossRefPubMed
14.
Psaty BM, Boineau R, Kuller LH, et al. The potential costs of upcoding for heart failure in the United States. Am J Cardiol 1999; 84: 108–9CrossRefPubMed
15.
Silverman E, Skinner J. Medicare upcoding and hospital ownership. J Health Econ 2004; 23(2): 369–89CrossRefPubMed
16.
West SL, Strom BL, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. New York (NY): John Wiley & Sons Ltd, 2005: 709–66
17.
Rancourt J. UnitedHealth’s i3 unit tapped by FDA to provide postmarketing surveillance. FDC Reports, Inc. The Pink Sheet Daily 2005 Sep 28. No. 6
18.
Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1998: 130–4
Metadata
Title
Bias due to False-Positive Diagnoses in an Automated Health Insurance Claims Database
Authors
Dr Stephan F. Lanes
Cynthia de Luise
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 11/2006
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200629110-00006

Other articles of this Issue 11/2006

Drug Safety 11/2006 Go to the issue

Original Research Article

Fluoroquinolone-Associated Anaphylaxis in Spontaneous Adverse Drug Reaction Reports in Germany

Original Research Article

Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients

Review Article

Interventions of Hospital Pharmacists in Improving Drug Therapy in Children

Review Article

Betahistine

Leading Article

Clarification of Terminology in Medication Errors

Commentary

Botanical Nomenclature in Pharmacovigilance and a Recommendation for Standardisation